Pharmacology  ·  Serotonin Pharmacology

Serotonin Biology, Synthesis, and Receptors

Biosynthesis pathway, receptor subtypes, physiological roles, and serotonin syndrome

Abbreviations: 5-HT = 5-hydroxytryptamine (serotonin)  ·  SERT = serotonin transporter  ·  MAO-A = monoamine oxidase A  ·  5-HIAA = 5-hydroxyindoleacetic acid  ·  IP3 = inositol trisphosphate  ·  NMS = neuroleptic malignant syndrome  ·  SSRI = selective serotonin reuptake inhibitor  ·  MAOI = monoamine oxidase inhibitor

Biosynthesis & Degradation
Substrate
Tryptophan
dietary amino acid
→
Step 1 (rate-limiting)
5-Hydroxytryptophan
tryptophan hydroxylase
→
Step 2
Serotonin
aromatic L-amino acid decarboxylase
→
Degradation
5-Hydroxyindoleacetic acid
monoamine oxidase A → urine
Storage Sites
Where Serotonin Is Found
  • Enterochromaffin cells — 90–95% of body serotonin; gut mucosa; initiates peristalsis
  • Platelets — uptake via SERT, no synthesis; amplifies aggregation
  • Raphe nuclei neurons — central nervous system; mood, sleep, appetite, pain
Key Principle
Blood-Brain Barrier Separation
  • Serotonin does NOT cross the blood-brain barrier
  • Central and peripheral serotonin pools are independent
  • Plasma serotonin does not reflect CNS tone
  • 5-HIAA in urine reflects gut turnover only
Receptor Subtypes
Receptor Coupling Effect Drug Actions Clinical Note
5-HT1A/B/D Gi — inhibitory Reduce cyclic AMP; hyperpolarization Buspirone (5-HT1A agonist); triptans (5-HT1B/1D agonists) Autoreceptor desensitization explains SSRI lag; triptans abort migraine
5-HT2A/2B Gq — excitatory Increase IP3; smooth muscle contraction Atypical antipsychotics (5-HT2A antagonists); cyproheptadine 5-HT2A: serotonin syndrome neuromuscular features; 5-HT2B: valvulopathy
5-HT3 Ion channel (not G-protein coupled) Rapid depolarization; Na⁺/K⁺/Ca²⁺ influx Ondansetron, granisetron, palonosetron (antagonists) Chemotherapy-induced nausea and vomiting; only ionotropic serotonin receptor
5-HT4 Gs — stimulatory Increase cyclic AMP; gut prokinesis Metoclopramide (partial agonist); prucalopride (selective agonist) Accelerates gastric emptying; target for gastroparesis and constipation
Serotonin Syndrome
Clinical Triad
Serotonin Syndrome
  • Neuromuscular — clonus (most specific), hyperreflexia, tremor
  • Autonomic — hyperthermia, tachycardia, diaphoresis, hypertension
  • Mental status — agitation, anxiety, confusion
  • Onset — rapid (hours); caused by excess serotonergic activity
Treatment & Causes
Management
  • Stop all serotonergic agents immediately
  • Cyproheptadine — 5-HT2 antagonist; first-line pharmacological treatment
  • Benzodiazepines — agitation and neuromuscular hyperactivity
  • Cooling — for hyperthermia
  • Classic cause: SSRI + MAOI combination
Key Distinction: Serotonin Syndrome vs. NMS

Serotonin syndrome: clonus & hyperreflexia — caused by serotonergic excess — onset hours — treat with cyproheptadine.
Neuroleptic malignant syndrome: lead-pipe rigidity — caused by dopamine antagonists — onset days — treat with dantrolene or bromocriptine.

Suggested References

Author / Organization Title Source
Katzung BG (ed) Basic and Clinical Pharmacology, 15th ed. Chapter 16: Serotonin, the Ergot Alkaloids, and Other Vasoactive Substances McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 15: 5-Hydroxytryptamine (Serotonin) McGraw-Hill, 2023
Walther DJ, Bader M A unique central tryptophan hydroxylase isoform Biochem Pharmacol. 2003;66(9):1673–1680
Kulke MH, Hörsch D, Caplin ME, et al Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome J Clin Oncol. 2017;35(1):14–23
Roth BL, Hanizavareh SM, Blum AE Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology. 2004;174(1):17–24
Andrade C, Sandarsh S, Chethan KB, Nagesh KS Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians J Clin Psychiatry. 2010;71(12):1565–1575